| Shi, Shaojun |
NCT04126538: Pirfenidone Capsule in Patients With Chronic Kidney Disease G2 and G3a Study on Safety and Pharmacokinetics |
|
|
| Recruiting | 1 | 24 | RoW | pirfenidone capsule | Beijing Continent Pharmaceutical Co, Ltd. | Renal Insufficiency | 11/21 | 06/22 | | |
NCT06360874: A Study to Evaluate Safety, Tolerability and Pharmacokinetic of ND-003 Tablets in Healthy Adults |
|
|
| Enrolling by invitation | 1 | 104 | RoW | ND-003 40mg, ND-003 placebo 40mg, ND-003 80mg, ND-003 placebo 80mg, ND-003 160mg, ND-003 placebo 160mg, ND-003 240mg, ND-003 placebo 240mg, ND-003 300mg, ND-003 placebo 300mg, MAD_ND003_Dose 1, MAD_placebo_Dose 1, MAD_ND003_Dose 2, MAD_placebo_Dose 2, MAD_ND003_Dose 3, MAD_ placebo_Dose 3, Food effect_Cohort 1, Food effect_Cohort 2 | Shenzhen NewDEL Biotech, Co., Ltd, Shenzhen Innovation Center for Small Molecule Drug Discovery Co., Ltd. | Healthy | 12/24 | 02/25 | | |
| Tao, Juan |
NCT05793892: Efficacy and Safety of Lidocaine and Tetracaine Cream for Facial Laser Aesthetics in Chinese Adults |
|
|
| Completed | 3 | 286 | RoW | Lidocaine tetracaine cream, test drug:CU-30101, control drug:Pliaglis | Cutia Therapeutics（Wuxi）Co.,Ltd | Analgesia | 08/23 | 10/23 | | |
| Recruiting | 3 | 1300 | Europe, Canada, Japan, US, RoW | TAK-279 | Takeda | Plaque Psoriasis | 05/26 | 05/26 | | |
NCT06088043: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment |
|
|
| Active, not recruiting | 3 | 693 | Europe, Canada, Japan, US, RoW | TAK-279, Placebo, Apremilast | Takeda | Plaque Psoriasis | 08/25 | 04/26 | | |
NCT06454357: A Clinical Study of B007 in the Treatment of Pemphigus. |
|
|
| Recruiting | 2/3 | 132 | RoW | B007 | Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd | Pemphigus | 12/26 | 12/26 | | |
NCT05763550: To Evaluate the Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Herpetic Neuralgia |
|
|
| Completed | 2 | 331 | RoW | HSK16149 20mg BID, HSK16149 40mg BID, Pregabalin 150mg | Haisco Pharmaceutical Group Co., Ltd. | Herpetic Neuralgia | 06/23 | 08/23 | | |
NCT05093855: Efficacy and Safety Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) |
|
|
| Completed | 2 | 41 | RoW | BDB-001 Injection | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Hidradenitis Suppurativa | 08/23 | 08/23 | | |
NCT05103423: Safety and Efficacy Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) |
|
|
| Completed | 1/2 | 50 | RoW | BDB-001 Injection, Placebo | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Hidradenitis Suppurativa | 07/23 | 07/23 | | |
NCT06033573: Preoperative Assessment of Pathological Nipple Discharge With Delayed Ductal Imaging of Contrast-enhanced Mammography |
|
|
| Recruiting | N/A | 60 | RoW | contrast-enhanced spectral mammography | Wuhan Union Hospital, China | Nipple Discharge | 08/24 | 08/24 | | |
| Recruiting | N/A | 10000 | RoW | NIS | Second Affiliated Hospital, School of Medicine, Zhejiang University | Psoriasis | 07/30 | 07/30 | | |
| Zhang, Mingchang |
NCT05629390: Trial to Evaluate the Efficacy and Safety of TP-03, LIBRA Study |
|
|
| Completed | 3 | 163 | RoW | Lotilaner, TP-03, S-Misoxam, Vehicle Control | LianBio LLC | Blepharitis | 09/23 | 04/24 | | |
NCT06717152: Efficacy and Safety of SJP-0132 Eye Drops in Chinese Patients With Dry Eye Disease |
|
|
| Recruiting | 3 | 400 | RoW | SJP-0132, Placebo | Senju Pharmaceutical Science & Technology (Beijing) Co., Ltd., Senju Pharmaceutical Co., Ltd. | Dry Eye | 07/25 | 08/25 | | |
NCT05456425: A Clinical Trial on Safety and Efficacy of CBT-001 in Patients With Pterygium |
|
|
| Recruiting | 3 | 600 | US, RoW | CBT-001, Vehicle | Cloudbreak Therapeutics, LLC | Pterygium | 12/25 | 12/26 | | |
